Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: Results from the Veterans Affairs Study to Improve Anticoagulation

Chest

Volumn 140, Issue 2, 2011, Pages 359-365

  Rose, Adam J ^a,b   Ozonoff, Al ^a,c   Berlowitz, Dan R ^a,b   Ash, Arlene S ^b,d   Reisman, Joel I ^a   Hylek, Elaine M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; TIME; TREATMENT DURATION; UNITED STATES;

EID: 80051518203     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2738     Document Type: Article

References (22)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl 6):160S-198S. (Pubitemid 351892967)
2. Fuster V, Rydén LE, Cannom DS, et al American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.
3. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl 6):454S-545S. (Pubitemid 351892971)
4. Salem DN, O'Gara PT, Madias C, Pauker SG; American College of Chest Physicians. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl 6):593S-629S. (Pubitemid 351892973)
5. Singer DE, Albers GW, Dalen JE, et al American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl 6):546S-592S. (Pubitemid 351892972)
6. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167(13):1414-1419. (Pubitemid 47052441)
7. Hirsh J, Bates SM. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med. 2001;134(5):409-417. (Pubitemid 32179480)
8. Connolly SJ, Pogue J, Eikelboom J, et al; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029-2037.
9. van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost. 2008;6(3):451-456. (Pubitemid 351280112)
10. van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest. 2007;131(5):1508-1515. (Pubitemid 46762360)
11. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128(4):513-519. (Pubitemid 40283170)
12. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-245.
13. Baglin TP, Keeling DM, Watson HG; British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol. 2006;132(3):277-285. (Pubitemid 43381534)
14. Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost. 2009;7(1):94-101.
15. Fitzmaurice DA. Oral anticoagulation should be managed in the community with treatment aimed at standard therapeutic targets and increased recall intervals. J Thromb Haemost.2008;6(10):1645-1646.
16. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008;6(10):1647- 1654.
17. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost.2010;8(10):2182-2191.
18. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans AffaiRs study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4(1):22-29
19. Department of Veterans Affairs, Veterans Health Administration. Anticoagulation therapy management. Washington, DC: US Department of Veterans Affairs; 2009. VHA Directive 2009-003.
20. Rosendaal FR, Cannegieter SC, van der Meer FJ, Brie¨t E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239. (Pubitemid 23069000)
21. Witt DM, Delate T, Clark NP, et al Warfarin Associated Research Projects and Other Endeavors (WARPED) Consortium. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009;114(5):952-956.
22. National Institutes of Health Clinical Center. Prolongation of the interval between monitoring of warfarin in stable patients. NCT00356759. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2010. http://www.clinicaltrials.gov.